ASO Drug Targets ALS and FTD Neuronal Hyperexcitability
Northwestern researchers found a way to calm overactive neurons and restore neuronal activity, potentially slowing disease progression.
A new study at Northwestern University used patient nervous tissue and lab-grown human neurons to investigate how the TDP-43 protein drives overactive nerve cells in ALS and FTD.
- ALS affects about 350,000 people worldwide, causing progressive weakness and muscle atrophy.
- The study's findings explain why nerve cells overfire in ALS and FTD and highlight a promising new drug to slow or prevent disease progression.
No direct quote available in the text.
Author's summary: Researchers calm overactive neurons in ALS and FTD.
More News
- Jack Osbourne breaks silence on jungle feud with Kelly Brook
- How to watch Islanders vs. Lightning: TV channel and streaming options for December 6
- Tampa Bay Lightning vs. New York Islanders - Game Highlights
- Lightning vs. Islanders Prediction, Odds, Picks - Dec. 6
- Kelly Vedovelli révèle sa vie amoureuse
- F1 2026 : Lancements, livrées et premiers indices d'une révolution en piste
- JUST IN: Kelly Olynyk has been waived by the San Antonio Spurs
- Pelicans' Questionable Offseason Trade Looks Better After Saddiq Bey's Rise
- Spurs' Luke Kornet out Friday
- NBA: Spurs at Timberwolves